Is it safe to co‑administer methotrexate with amiodarone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Methotrexate and Amiodarone Co-Administration

Yes, methotrexate can be used with amiodarone, but this combination requires close monitoring due to a documented pharmacokinetic interaction that increases methotrexate exposure and potential toxicity risk.

The Drug Interaction

Amiodarone is a potent inhibitor of multiple cytochrome P450 pathways (CYP3A4, CYP2C9, CYP2D6) and P-glycoprotein 1, 2. While methotrexate is primarily renally eliminated, amiodarone has been shown to impair both hepatic and renal clearance of methotrexate. In animal studies, amiodarone decreased methotrexate's biliary clearance to 73% of control values and reduced total clearance to 72%, resulting in significantly elevated plasma methotrexate concentrations 3. Recent PBPK modeling confirms that amiodarone co-administration can increase steady-state methotrexate exposure 4.

Clinical Significance

The FDA label for amiodarone explicitly states that chronic oral amiodarone administration (>2 weeks) impairs metabolism of methotrexate 2. This interaction is particularly concerning because:

  • Methotrexate has a narrow therapeutic window with serious dose-related toxicities including bone marrow suppression, hepatotoxicity, and pulmonary toxicity 5
  • Both drugs independently cause hepatotoxicity, creating additive risk 6, 5
  • Amiodarone's extremely long half-life (weeks to months) means the interaction persists long after discontinuation

Management Algorithm

When co-prescribing is necessary:

  1. Baseline Assessment

    • Complete blood count with differential and platelets
    • Comprehensive metabolic panel including creatinine and liver enzymes (AST, ALT)
    • Thyroid function tests (TSH, free T4) - both drugs affect thyroid 1, 7
    • Chest radiograph if not recently performed 1
  2. Enhanced Monitoring Schedule

    • CBC and liver enzymes: every 2 weeks for the first 2 months, then monthly 7, 8
    • Renal function: every 2-3 months 7
    • Thyroid function: every 6 months (standard for amiodarone) 1
    • Watch specifically for signs of methotrexate toxicity: mucositis, cytopenias, elevated transaminases
  3. Methotrexate Dosing Considerations

    • Consider starting at the lower end of the therapeutic range
    • Ensure adequate folic acid supplementation (1-5 mg daily, except on methotrexate dosing day) 7
    • Maintain excellent hydration status 9
  4. Red Flags Requiring Immediate Action

    • WBC <3.0 × 10⁹/L or neutrophils <1.0 × 10⁹/L: withhold methotrexate 8
    • Platelets <100 × 10⁹/L: withhold methotrexate 8
    • AST/ALT >2-3× upper limit of normal: withhold methotrexate 8
    • New pulmonary symptoms (dry cough, dyspnea): withhold both drugs and investigate urgently 1, 5, 2
    • Severe mucositis or diarrhea: withhold methotrexate immediately 5

Critical Caveats

Avoid this combination in patients with:

  • Pre-existing significant liver disease (both drugs contraindicated) 6, 5
  • Renal impairment (CrCl <60 mL/min) - methotrexate elimination is critically dependent on renal function 7, 5
  • Active pulmonary disease - both drugs cause pulmonary toxicity 6, 5, 2

Additional risk factors requiring extreme caution:

  • Concurrent NSAIDs (further impair methotrexate clearance, though short-term use appears safer) 7, 10
  • Dehydration or volume depletion
  • Diabetes mellitus 7
  • Obesity 7

Alternative Considerations

If the patient requires amiodarone for life-threatening arrhythmias and methotrexate for severe rheumatoid arthritis or psoriasis, consultation with both cardiology and rheumatology/dermatology is essential to weigh risks versus benefits. Consider whether alternative immunosuppressants (leflunomide, biologics) could replace methotrexate 11, or whether alternative antiarrhythmics could replace amiodarone 6.

The interaction is real and clinically significant, but the combination is not absolutely contraindicated - it simply demands vigilant monitoring and a lower threshold for intervention when toxicity signals emerge.

References

Guideline

amiodarone: guidelines for use and monitoring.

American family physician, 2003

Research

Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats.

Biopharmaceutics & drug disposition, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.